![](/img/cover-not-exists.png)
Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in NSCLC EGFR -mutated patient
Minari, Roberta, Bordi, Paola, La Monica, Silvia, Squadrilli, Anna, Leonetti, Alessandro, Bottarelli, Lorena, Azzoni, Cinzia, Lagrasta, Constanza Anna Maria, Gnetti, Lelizia, Campanini, Nicoletta, PetLanguage:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2018.03.013
Date:
March, 2018
File:
PDF, 1.20 MB
english, 2018